Overview
Lobbying Costs
17,500€
Financial year: Jan 2019 - Dec 2019
Lobbyists (Full time equivalent)
0.25 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
9
Lobbying Costs over the years
-
Info
CureVac AG
EU Transparency Register
798772637872-28 First registered on 17 Apr 2020
Goals / Remit
CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases: At CureVac, we aim to leverage our unique technology to provide life-saving solutions for patients with the greatest need. That is why we are moving forward with a strategic, purposeful mRNA-based pipeline focusing on four therapeutic areas: The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. Partnerships with pharmaceutical, other biotechnology companies and non-profit organizations who share our mission, help extend the reach of our technology to affect more people globally: We have received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, CEPI and others. CureVac currently employs around 470 people (April 2020) and the company is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
Main EU files targeted
Current activities: Interactions with European Commission and EIB to financially support upscaling manufacturing capacity for mRNA drugs – inter alia for vaccines.
Past activities: FP7-HEALTH-2013-INNOVATION-1 (EU grant) and EFPIA (membership).Address
Head Office
Paul-Ehrlich-Str. 15
Tübingen 72076
GERMANY -
People
Total lobbyists declared
1
Employment time Lobbyists 25% 1 Lobbyists (Full time equivalent)
0.25
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
N/A
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Companies & groups
-
Networking
Affiliation
0
Member organisations
- Vfa. Die forschenden Pharma-Unternehmen
- Bio Deutschland
- Wissensfabrik - Unternehmen für Deutschland e.V.
- Controlled Release Society (CRS)
- Verein zur Förderung der Biotechnologie
- Dechema Gesellschaft für Chemische Technik und Biotechnologie -
Financial Data
Closed financial year
Jan 2019 - Dec 2019
Lobbying costs for closed financial year
17,500€
EU grant income for closed financial year
44 € (Source: international)
Other financial info
N/A
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
N/A
Other activities
N/A
Meetings
Meetings
9 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 30 Nov 2022 Location Brussels Subject Medicines manufacturing and pandemic preparedness Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Maurits-Jan Prinz (Cabinet member)
-
Date 02 Mar 2021 Location Videoconference Subject Vaccine production Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Thierry Breton (Commissioner)
Other Lobbyists -
Date 08 Feb 2021 Location webex Subject meeting with Curevac - vaccines DG Health and Food Safety Attending - Sandra Gallina (Director-General)
-
Date 31 Jan 2021 Location Videoconference Subject Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
Other Lobbyists -
Date 06 Jul 2020 Location Video-conferencing Subject CureVac Signature Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Mariya Gabriel (Commissioner)
-
Date 06 Jul 2020 Location Video-conferencing Subject CureVac Signature Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Innovation and Youth Attending - Mariya Gabriel (Commissioner)
-
Date 16 Mar 2020 Location video-conferencing Subject COVID-19 Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Digital Economy and Society Attending - Mariya Gabriel (Commissioner)
-
Date 16 Mar 2020 Location Videoconference Subject Videconderence with CureVac representatives on COVID-19 Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Ursula von der Leyen (President)
-
Date 16 Mar 2020 Location video-conferencing Subject COVID-19 Cabinet Cabinet of Commissioner Mariya Gabriel Portfolio Innovation and Youth Attending - Mariya Gabriel (Commissioner)